The Advanced Integrative Molecular Probe Collaboration's mission is to develop new imaging agents in a multidisciplinary approach to monitor, understand and cure disease at an early stage.
Our research endeavors are dedicated to pioneering the development of virtual reality simulators tailored for surgical training, harnessing the power of cutting-edge technologies such as artificial intelligence, automated systems, and advanced deep learning algorithms. Central to our work is the creation of AI-driven solutions for automated surgical video segmentation, precise identification of anatomical structures, surgical tool recognition, and comprehensive skills assessment.
Akbay Lab studies genetic and molecular events that lead to lung-tumor initiation and immune evasion.
Understanding brain circuits in disease and cognition to develop restorative neuromodulation.
Our mission is to improve the care of breast cancer patients through cutting-edge translational research at the interface of clinical oncology, cancer biology, molecular genetics, and translational genomics.
Our goal is to track the signaling dynamics of individual effectors and toxins in living cells, using a combination of fluorescent genetic reporters, microinjection of labeled bacterial proteins, and live cell imaging techniques.
Our group initially investigated a novel immune checkpoint inhibitor targeting a rare heparan sulfate (rHS) in melanoma treatment. Collaboratively, we explored the potential of a single-domain humanized rHS antibody (1A7 clone) that inhibits DC-HIL function and also angiogenesis and chemokine effects linked to diverse cancer progression signaling pathways. This experience provided insights into rHS-targeting as a promising approach to melanoma therapy.
The Arteaga laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies.
The central goal of Dr. Asch's research is to uncover the mechanistic underpinnings of how stress and trauma affect brain function, with a particular emphasis on how these experiences shape mental health outcomes with the aim to contribute to the development of novel interventions designed to mitigate the harmful effects of stress and trauma, foster resilience, and ultimately improve overall
health and well-being.
Multidisciplinary research to beat cancer
The Neuro-Oncology Translational Research Laboratory studies primary brain tumors from pure basic science through the continuum to clinical trials.
Our goal is to employ cryo-EM to determine high resolution structures of important membrane protein complexes involved in cellular signaling, including cellular receptors and ion channels. We also combine structural approaches with functional studies to reveal the structure-function relationships of these membrane proteins.
The Bailey lab focuses on developing gene therapies for neurological disorders. We work on monogenetic pediatric disorders, including SLC13A5 epileptic encephalopathy, multiple sulfatase deficiency, Charcot Marie Tooth disease type 4J, giant axonal neuropathy and ECHS1 deficiency.
We study the role of chromatin regulation in cell fate decisions.
The Bann Laboratory focuses on discovering novel mechanistic targets to treat heart failure. We aim to identify regulators of cardiac cell fate reprogramming and regeneration as a molecular strategy to repair and heal the heart following injury.
Neuron-cancer interactions that promote tumor growth and disrupt neural circuits.
The Bartelt Lab is focused on understanding the epigenetic basis of cerebellar neurodegenerative disorders to develop holistic gene therapies. Using single-cell and spatial sequencing approaches, we profile healthy and diseased states to identify gene regulatory mechanisms in disease and utilize functional genomic tools to advance therapeutic approaches.
Our laboratory has characterized many of the transporters responsible for proximal tubule acidification and solute transport
The Beckham lab is a dynamic multidisciplinary laboratory that studies viral pathogenesis and neuroimmune responses.
Dr. Bedimo studies strategies for optimally managing drug-resistant HIV patients, analyzing metabolic abnormalities in HIV patients, and studying the effects of HCV co-infection.
We combine classical genetics with modern technology to understand human physiology and search for breakthrough treatments for diseases.
The Bezerra Lab current studies investigate how developmental defects increase the susceptibility of the biliary epithelium to infectious and toxic insults.
The Bioinformatics Lab provides services to manage and analyze next-generation sequencing data.
